Manufacturing Baxter Enters Into Manufacturing Agreement for Novavax’ COVID-19 Vaccine

Baxter Enters Into Manufacturing Agreement for Novavax’ COVID-19 Vaccine

-

Baxter BioPharma Solutions has entered into an agreement to provide sterile manufacturing services for NVX-CoV2373, Novavax’ COVID-19 recombinant nanoparticle vaccine candidate with Matrix-M adjuvant.

Baxter BioPharma Solutions is a contract manufacturing organization that specializes in parenteral pharmaceuticals, including vaccines.

“We welcome the opportunity to work with an innovative company like Novavax and look forward to helping bring their vaccine candidate to the market.” According to Novavax, NVX-CoV2373 contains a full-length, prefusion spike protein made using Novavax’s recombinant nanoparticle technology and the company’s proprietary saponin-based Matrix-M adjuvant.

“Partners like Baxter BioPharma Solutions are enabling Novavax to quickly establish a commercial supply chain network to ensure access for global populations, and ultimately help bring about an end to the global COVID19 pandemic.” Baxter’s manufacturing services for NVX-CoV2373 will take place at its state-of-the-art facility in Halle/Westfalen, Germany.

The site has broad sterile manufacturing capabilities and areas of focus, offers current good manufacturing practices manufacturing with dedicated production areas, and is designed to deliver products with optimum efficiency and speed to market.

Read Full article here

Latest news

Patient-Centric Clinical Trials And The Role Of A Travel Concierge

Many people find booking plane tickets, arranging road transportation and overnight lodging overwhelming. Add into that mix...

China forces insulin price cuts resulting in pullback for global pharma players

Xinhua, a Chinese news channel, commented on the price cut on insulin which was brought on by...

Aussie pharma CSL in talks to buy Swiss firm Vifor Pharma for USD 7B

CSL, the Australian giant, is in talks to buy Vifor Pharma in a deal that is valued...
- Advertisement -

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

Amgen’s KRAS drug gets early FDA approval for lung cancer with specific mutation

On Friday, the United States FDA (Food and Drug Administration) has authorized a medication of Amgen Biopharmaceutical in patients with NSCLC

You might also likeRELATED
Recommended to you